Abstract
Aptamers, or nucleic acid ligands, have gained clinical interest over the past 20 years due to their unique characteristics, which are a combination of the best facets of small molecules and antibodies. The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Here we review the various methods of antidote control of aptamer therapeutics – matched oligonucleotide antidotes and universal antidotes. We also describe the development, recent progress, and potential future therapeutic applications of these types of aptamer-antidote pairs.
Keywords: Anticoagulant, antidote, antiplatelet, aptamer, oligonucleotide antidote, therapeutic, universal antidote, nucleic acid ligands, small molecules, antibodies, aptamer-antidote pairs, viral RNA, oligonucleotides, therapeutic target, clinical interest.
Current Pharmaceutical Biotechnology
Title:Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Volume: 13 Issue: 10
Author(s): K. M. Bompiani, R. S. Woodruff, R. C. Becker, S. M. Nimjee and B. A. Sullenger
Affiliation:
Keywords: Anticoagulant, antidote, antiplatelet, aptamer, oligonucleotide antidote, therapeutic, universal antidote, nucleic acid ligands, small molecules, antibodies, aptamer-antidote pairs, viral RNA, oligonucleotides, therapeutic target, clinical interest.
Abstract: Aptamers, or nucleic acid ligands, have gained clinical interest over the past 20 years due to their unique characteristics, which are a combination of the best facets of small molecules and antibodies. The high binding affinity and specificity of aptamers allows for isolation of an artificial ligand for theoretically any therapeutic target of interest. Chemical manipulations of aptamers also allow for fine-tuning of their bioavailability, and antidote control greatly expands their clinical use. Here we review the various methods of antidote control of aptamer therapeutics – matched oligonucleotide antidotes and universal antidotes. We also describe the development, recent progress, and potential future therapeutic applications of these types of aptamer-antidote pairs.
Export Options
About this article
Cite this article as:
M. Bompiani K., S. Woodruff R., C. Becker R., M. Nimjee S. and A. Sullenger B., Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273137
DOI https://dx.doi.org/10.2174/138920112802273137 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Dermatological, Cardiovascular and Neurological Morphohistopathological Effects of Fluoropyrimidine-based Chemotherapy in Humans
Clinical Cancer Drugs Molecular Dissection of Renal Ischemia-Reperfusion: Oxidative Stress and Cellular Events
Current Medicinal Chemistry Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Synthesis of 5-Arylidene Barbiturates: A Novel Class of DPPH Radical Scavengers
Letters in Drug Design & Discovery Pharmacological and Surgical Therapy for Primary Postpartum Hemorrhage
Current Pharmaceutical Design Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Stress Echocardiography
Current Pharmaceutical Design The Roles of Neurotensin and its Analogues in Pain
Current Pharmaceutical Design The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry The Concept of Titration can be Transposed to Fluid Management. But does is Change the Volumes? Randomised Trial on Pleth Variability Index During Fast-Track Colonic Surgery
Current Clinical Pharmacology N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Off-Pump Coronary Artery Bypass Grafting; is it Still Relevant?
Current Cardiology Reviews Syntheses of Amido-, Carbamido- and Carbamatoalkylnaphthols
Current Organic Synthesis Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology